Literature DB >> 895195

Clinical features and management of cystinuria.

P J Dahlberg, S B Kurtz, D M Wilson, L H Smith.   

Abstract

Cystinuria is a complex hereditary disorder that affects both sexes with equal frequency and severity. Symptoms usually begin early (children and young adults) but may develop at any age. Stature is normal and there are no clinical nutritional abnormalities. The morbidity of cystine urolithiasis is considerable. Hyperuricemia is a frequent associated finding and is probably the result of multiple factors. No other abnormalities are consistently related to this disease. Treatment with adequate oral fluids to ensure a copious urine volume and with oral alkali to keep the urine alkaline is most successful when used prophylactically in the stone-free patient. However, dissolution of existing calculi is unlikely with this regimen alone. The addition of D-penicillamine often results in dissolution of stones and prevention of recurrent calculi in patients who have continued stone growth despite the use of oral fluids and alkali. Because toxic reactions with D-penicillamine are frequent and sometimes severe, this drug should be used only when necessary and then as an adjunct to rather than a substitute for increased oral fluids and alkali. Failure of treatment in spite of adequate therapy should alert the physician to the possibility of coexisting complicating problem.

Entities:  

Mesh:

Year:  1977        PMID: 895195

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  31 in total

Review 1.  Evaluation of urinary tract calculi in children.

Authors:  S A Hulton
Journal:  Arch Dis Child       Date:  2001-04       Impact factor: 3.791

2.  Urine proteomic profiling in patients with nephrolithiasis and cystinuria.

Authors:  Larisa Kovacevic; Joseph A Caruso; Hong Lu; Natalija Kovacevic; Yegappan Lakshmanan; Nicholas J Carruthers; David S Goldfarb
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

Review 3.  Pharmacotherapy of urolithiasis: evidence from clinical trials.

Authors:  Orson W Moe; Margaret S Pearle; Khashayar Sakhaee
Journal:  Kidney Int       Date:  2010-10-06       Impact factor: 10.612

4.  Urinary excretion of total cystine and the dibasic amino acids arginine, lysine and ornithine in relation to genetic findings in patients with cystinuria treated with sulfhydryl compounds.

Authors:  Erik Fjellstedt; Lotta Harnevik; Jan-Olof Jeppsson; Hans-Göran Tiselius; Peter Söderkvist; Torsten Denneberg
Journal:  Urol Res       Date:  2003-10-25

5.  Molecular analysis of cystinuria in Libyan Jews: exclusion of the SLC3A1 gene and mapping of a new locus on 19q.

Authors:  R Wartenfeld; E Golomb; G Katz; S J Bale; B Goldman; M Pras; D L Kastner; E Pras
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

6.  Evidence suggesting that the minimal functional unit of a renal cystine transporter is a heterodimer and its implications in cystinuria.

Authors:  S S Tate
Journal:  Amino Acids       Date:  1996-06       Impact factor: 3.520

Review 7.  Urolithiasis in children: current medical management.

Authors:  J Laufer; H Boichis
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

8.  Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children.

Authors:  Ralph J DeBerardinis; Curtis R Coughlin; Paige Kaplan
Journal:  J Urol       Date:  2008-10-31       Impact factor: 7.450

9.  Cystinuria: the South Indian experience.

Authors:  Y M Fazil Marickar
Journal:  Urol Res       Date:  2009-09-25

Review 10.  How should patients with cystine stone disease be evaluated and treated in the twenty-first century?

Authors:  Kim Hovgaard Andreassen; Katja Venborg Pedersen; Susanne Sloth Osther; Helene Ulrik Jung; Søren Kissow Lildal; Palle Joern Sloth Osther
Journal:  Urolithiasis       Date:  2015-11-27       Impact factor: 3.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.